Our results characterize a novel antiviral function for TFII-I against HAdV that occurs during the early stage of the viral replication cycle and highlight the importance of studying viral countermeasures to the cellular antiviral response, like E4ORF3, to better understand how cells restrict viral infection. This evidence concerns the gene GTF2I and viral infectious disease.